What is the composition of Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Composition of Lo Loestrin Fe

Lo Loestrin Fe contains norethindrone acetate 1 mg and ethinyl estradiol 10 micrograms as its active hormonal ingredients, along with ferrous fumarate tablets for the placebo phase.

Lo Loestrin Fe is a combined oral contraceptive (COC) that features one of the lowest doses of ethinyl estradiol available in any oral contraceptive on the market. Its composition includes:

Active Hormonal Components

  • Norethindrone acetate: 1 mg

    • A first-generation progestin derived from testosterone
    • Functions as the progestin component that inhibits ovulation
  • Ethinyl estradiol: 10 micrograms

    • A synthetic estrogen component
    • Ultra-low dose compared to other COCs which typically contain 20-35 μg

Regimen Structure

Lo Loestrin Fe is packaged in a 28-day regimen consisting of:

  • 24 blue active tablets containing both norethindrone acetate and ethinyl estradiol
  • 2 white tablets containing only ethinyl estradiol (10 μg)
  • 2 brown tablets containing ferrous fumarate (iron supplement)

Mechanism of Action

As a combined oral contraceptive, Lo Loestrin Fe works through several mechanisms 1:

  • Inhibiting gonadotropin-releasing hormone, follicle-stimulating hormone, and luteinizing hormone
  • Preventing ovulation
  • Decreasing ovarian androgen production
  • Increasing sex hormone-binding globulin
  • Reducing free testosterone
  • Reducing 5α-reductase activity
  • Blocking androgen receptors

Clinical Context

Lo Loestrin Fe is FDA-approved for contraception and is one of four COCs that are also approved for the treatment of acne in women who desire oral contraception 1. The ultra-low dose of ethinyl estradiol (10 μg) makes it one of the lowest estrogen-containing COCs available, which may be beneficial for women who are sensitive to estrogen-related side effects.

Safety Considerations

  • The low estrogen dose may be associated with a potentially lower risk of estrogen-related side effects compared to higher-dose formulations
  • However, like all COCs, it carries risks including venous thromboembolism, with risk varying by estrogen dose and progestin type 1
  • Contraindicated in women with certain conditions including history of thromboembolism, uncontrolled hypertension, and certain types of migraines 1

Lo Loestrin Fe represents an ultra-low-dose oral contraceptive option that maintains contraceptive efficacy while potentially minimizing estrogen-related adverse effects 2.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.